Radioactive Iodine Dosimetry for Thyroid Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to predict the effectiveness of radioactive iodine treatment for metastatic thyroid cancer. It uses a form of iodine, 124-I, to measure the radiation each cancer spot will receive, aiding doctors in determining the best treatment plan. The goal is to avoid unnecessary radiation for patients unlikely to benefit and to customize the treatment dose for those who will. The primary treatment under study is 131-I, another form of radioactive iodine. The trial seeks adults with thyroid cancer who have had their thyroid removed and show iodine-absorbing cancer spots, confirmed by specific scans within the last six months. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative approach.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, patients who plan to withdraw from thyroid hormone before dosimetry are not eligible, suggesting that staying on thyroid hormone might be required.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that radioactive iodine, specifically 131-I, has treated thyroid cancer that has spread for over 50 years. Patients usually tolerate it well, though high doses can cause side effects like burns to the eyes and skin. Studies indicate that radiation exposure to people around patients receiving 131-I remains generally low and within safe limits.
Regarding 124-I, research has found it very safe for detecting thyroid cancer. It does not cause major side effects to the thyroid gland, the main organ it affects. This iodine type helps predict the effectiveness of 131-I treatment, potentially reducing unnecessary radiation exposure for some patients.
Both types of iodine have undergone thorough study. If concerns arise, discussing them with a healthcare provider before joining a trial is important.12345Why are researchers excited about this trial's treatments?
Most treatments for thyroid cancer involve surgery, chemotherapy, or the use of radioactive iodine (RAI) like 131-I. What makes 131-I iodine unique is its targeted approach, which allows it to specifically attack thyroid cancer cells with minimal impact on the rest of the body. Researchers are particularly excited about its potential for precise dosimetry, which means they can tailor the amount of radiation each patient receives for optimal effectiveness. This precision not only aims to improve treatment outcomes but also reduces the risk of side effects, making it a promising option for those battling thyroid cancer.
What evidence suggests that this trial's treatments could be effective for thyroid cancer?
This trial will evaluate the use of 131-I and 124-I for thyroid cancer. Studies have shown that 131-I is highly effective for treating thyroid cancer, especially when combined with surgery, with up to 90% of patients achieving remission. However, some patients may experience a recurrence after treatment. Meanwhile, 124-I proves very useful in detecting cancer spread, particularly with newer, more precise PET scanners. Research indicates that 124-I can identify patients who might not respond well to 131-I, potentially sparing them unnecessary radiation. This personalized approach aims to improve treatment success by tailoring radiation doses to each patient's needs.23678
Who Is on the Research Team?
Ravinder Grewal, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with thyroid cancer who've had their thyroid removed and previous treatment to eliminate remaining thyroid tissue. They must have metastases that absorb radioiodine, measurable disease documented in the last six months, and be planning further radioiodine therapy if needed. It's not for those under 18, pregnant, treated with radioiodine in the past nine months, or without metastases.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Imaging
Participants undergo diagnostic imaging with 124-I to determine radiation dosage for metastatic lesions
Treatment
Participants receive customized 131-I treatment based on 124-I dosimetry results
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- 124 I-iodine (124-I)
- 131 I-iodine (131-I)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Collaborator